• The Tumor immune microenvironment drives a prognostic relevance that correlates with bladder cancer subtypes

  Pfannstiel C, Strissel PL, Chiappinelli B, Sikic D, Wach S, Wirtz RM, Wullweber A, Taubert H, Breyer J, Otto W, Worst TS, Burger M, Wullich B, Bolenz C, Fuhrich N, Geppert C, Weyerer V, Stoehr R, Bertz S, Keck B, Erlmeier F, Erben P, Hartmann A, Strick R, Eckstein M
  Cancer Immunol Res. 2019 Jun;7(6):923‐938.
  DOI: 10.1158/2326-6066.CIR-18-0758
  PMID: 30988029
  

• Androgen Receptor mRNA expression in urothelial carcinoma of the bladder: a retrospective analysis of two independent cohorts

  Sikic D, Wirtz RM, Wach S, Dyrskjot L, Erben P, Bolenz C, Breyer J, Otto W, Hoadley KA, Lerner SP, Eckstein M, Hartmann A, Keck B
  Transl Oncol. 2019 Apr;12(4):661-668.
  DOI: 10.1016/j.tranon.2019.01.005
  PMID: 30831560
  

• Analysis of the prognostic relevance of sex-steroid hormonal receptor mRNA expression in muscle-invasive urothelial carcinoma of the urinary bladder

  Erben P, Sikic D, Wirtz RM, Martini T, Weis CA, Breyer J, Otto W, Keck B, Hartmann A, Bolenz C
  Virchows Arch. 2019 Feb;474(29, 209-217.
  DOI: 10.1007/s00428-018-2496-9
  PMID: 30483954
  

• Performance of the Food and Drug Administration/EMA-approved programmed cell death ligand-1 assays in urothelial carcinoma with emphasis on therapy stratification for first-line use of atezolizumab and pembrolizumab

  Eckstein M, Erben P, Kriegmair MC, Worst TS, Weiß CA, Wirtz RM, Wach S, Stoehr R, Sikic D, Geppert CI, Weyerer V, Bertz S, Breyer J, Otto W, Keck B, Burger M, Taubert H, Weichert W, Wullich B, Bolenz C, Hartmann A, Erlmeier F
  Eur J Cancer. 2019 Jan;106:234-243.
  DOI: 10.1016/j.ejca.2018.11.007
  PMID: 30528808
  

• Predictive value of lymphangiogenesis and proliferation markers on mRNA level in urothelial carcinoma of the bladder after radical cystectomy

  Martini T, Heinkele J, Mayr R, Weis CA, Wezel F, Wahby S, Eckstein M, Schnöller T, Breyer J, Wirtz R, Ritter M, Bolenz C, Erben P
  Urol Oncol. 2018 Dec;36(12):530.e19-530.e27.
  DOI: 10.1016/j.urolonc.2018.09.003
  PMID: 3044644
  

• mRNA-Expression of KRT5 and KRT20 Defines Distinct Prognostic Subgroups of Muscle-Invasive Urothelial Bladder Cancer Correlating with Histological Variants

  Eckstein M, Wirtz RM, Gross-Weege M, Breyer J, Otto W, Stoehr R, Sikic D, Keck B, Eidt S, Burger M, Bolenz C, Nitschke K, Porubsky S, Hartmann A, Erben P
  Int J Mol Sci. 2018 Oct 30;19(11):3396.
  DOI: 10.3390/ijms19113396
  PMID: 30380731
  

• CDKN2A as transcriptomic marker for muscle-invasive bladder cancer risk stratification and therapy decision-making

  Worst TS, Weis CA, Stöhr R, Bertz S, Eckstein M, Otto W, Breyer J, Hartmann A, Bolenz C, Wirtz RM, Erben P
  Sci Rep. 2018 Sept 26;8(1):14383.
  DOI: 10.1038/s41598-018-32569-x
  PMID: 30258198
  

• High CDKN2A/p16 and low FGFR3 expression predict progressive potential of stage pT1 urothelial bladder carcinoma

  Breyer J, Wirtz RM, Erben P, Worst TS, Stoehr R, Eckstein M, Bertz S, Sikic D, Denzinger S, Burger M, Hartmann A, Otto W
  Clin Genitourin Cancer. 2018 Aug;16(4),248-256e2.
  DOI: 10.1016/j.clgc.2018.01.009
  PMID: 29525349
  

• Infiltrative lamina propria invasion pattern as an independent predictor for cancer-specific and overall survival of instillation treatment-naïve stage T1 high-grade urothelial bladder cancer.

  Otto W, van Rhijn BW, Breyer J, Bertz S, Eckstein M, Mayr R, Lausenmeyer EM, Denzinger S, Burger M, Hartmann A
  Int J Urol. 2018 May;25(5):442-449.
  DOI: 10.1111/iju.13532
  PMID: 29473226
  

• Prognostic Value of molecular breast cancer subtypes based on Her2, PGR and Ki67 mRNA-Expression in muscle invasive bladder cancer

  Kriegmair MC, Wirtz RM, Worst TS, Breyer J, Ritter M, Keck B, Boehmer C, Otto W, Eckstein M, Weis CA, Hartmann A, Bolenz C, Erben P
  Transl Oncol. 2018 Apr;11(2):467-476.
  DOI: 10.1016/j.tranon.2018.02.001
  PMID: 29477637
  

• High PDL1 mRNA expression predicts better survival of stage pT1 non-muscle-invasive bladder cancer (NMIBC) patients

  Breyer J, Wirtz RM, Otto W, Erben P, Worst TS, Stoehr R, Eckstein M, Denzinger S, Burger M, Hartmann A
  Cancer Immunol Immunother. 2018 Mar;67(3):403-412.
  DOI: 10.1007/s00262-017-2093-9
  PMID: 29150702
  

• A multicenter round robin test of PD-L1 expression assessment in urothelial bladder cancer by immunohistochemistry and RT-qPCR with emphasis on prognosis prediction after radical cystectomy

  Eckstein M, Wirtz RM, Pfannstil C, Wach S, Stoehr R, Breyer J, Erlmeier F, Günes C, Nitschke K, Weichert W, Otto W, Keck B, Eidt S, Burger M, Taubert H, Wullich B, Bolenz C, Hartmann A, Erben P
  Oncotarget. 2018 Feb;19;9(19):15001-15014.
  DOI: 10.18632/oncotarget.24531
  PMID: 29599921
  

• FOXM1 predicts overall and diseases specific survival in muscle-invasive urothelial carcinoma and presents a differential expression between bladder cancer subtypes

  Rinaldetti S, Wirtz RM, Worst TS, Eckstein M, Weiss CA, Breyer J, Otto W, Bolenz C, Hartmann A, Erben P
  Oncotarget. 2017 Jul 18;8(29):47595-47606.
  DOI: 10.18632/oncotarget.17394
  PMID: 28498805
  

• Immunohistochemical subtyping using CK20 and CK5 can identify urothelial carcinomas of the upper urinary tract with a poor prognosis

  Sikic D, Keck B, Wach S, Taubert H, Wullich B, Goebell PJ, Kahlmeyer A, Olbert P, Isfort P, Nimphius W, Hartmann A, Giedl J
  PLoS One. 2017 Jun 20;12(6):e0179602.
  DOI: 10.1371/journal.pone.0179602
  PMID: 28632777
  

• High androgen receptor mRNA expression is independently associated with prolonged cancer-specific and recurrence-free survival in stage T1 bladder cancer

  Sikic D, Breyer J, Hartmann A, Burger M, Erben P, Denzinger S, Eckstein M, Stoehr R, Wach S, Wullich B, Keck B, Wirtz RM, Otto W
  Trans Oncol. 2017 Jun;10(3):340-345.
  DOI: 10.1016/j.tranon.2017.01.013
  PMID: 28342317
  

• Predictive value of molecular subtyping in NMIBC by RT-qPCR of ERBB2, ESR1, PGR and MKI67 from formalin-fixed TUR biopsies.

  Breyer J, Wirtz RM, Otto W, Laible M, Schlombs K, Erben P, Kriegmair MC, Stoehr R, Eidt S, Denzinger S, Burger M, Hartmann A
  Oncotarget. 2017 Jun 28;8(40):67684-67695.
  DOI: 10.18632/oncotarget.18804
  PMID: 28978063
  

• In stage pT1 non-muscle-invasive bladder cancer (NMIBC), high KRT20 and low KRT5 mRNA expression identify the luminal subtype and predict recurrence and survival

  Breyer J, Wirtz RM, Otto W, Erben P, Kriegmair MC, Stoehr R, Eckstein M, Eidt S, Denzinger S, Burger M, Hartmann A
  Virchows Arch. 2017 Mar;470(3):267-274.
  DOI: 10.1007/s00428-017-2064-8
  PMID: 28074276
  

• ERBB2 Expression as Potential Risk-Stratification for Early Cystectomy in Patients with pT1 Bladder Cancer and Concomitant Carcinoma in situ

  Breyer J, Otto W, Wirtz RM, Wullich B, Keck B, Erben P, Kriegmair MC, Stoehr R, Eckstein M, Laible M, Schlombs K, Eidt S, Denzinger S, Burger M, Hartmann A
  Urol Int. 2017;98(3):282-289.
  DOI: 10.1159/000453670
  PMID: 27992871
  

• ESR1, ERBB2, and Ki67 mRNA expression predicts stage and grade of non-muscle-invasive bladder carcinoma (NMIBC).

  Breyer J, Wirtz RM, Laible M, Schlombs K, Erben P, Kriegmair MC, Stoehr R, Eidt S, Denzinger S, Burger M, Hartmann A, Otto W
  Virchows Arch. 2016 Nov;469(5):547-552.
  DOI: 10.1007/s00428-016-2002-1
  PMID: 27514658
  

• Expression of the p53 Inhibitors MDM2 and MDM4 as Outcome Predictor in Muscle-invasive Bladder Cancer

  Kriegmair MC, Balk M, Wirtz R, Steidler A, Weis CA, Breyer J, Hartmann A, Bolenz C, Erben P
  Anticancer Res. 2016 Oct;36(10):5205-5213.
  DOI: 10.21873/anticanres.11091
  PMID: 27798881
  

• Molekulare Klassifikation des Harnblasenkarzinoms - Mögliche Ähnlichkeit zum Mammakarzinom

  Wirtz RM, Fritz V, Stöhr R, Hartmann A
  Pathologe. 2016 Feb;37(1):52-60.
  DOI: 10.1007/s00292-015-0134-8
  PMID: 26780243